ArticleFrontiers in nutrition2025
High intake of n-6 polyunsaturated fatty acid exacerbates non-alcoholic steatohepatitis by the involvement of multiple metabolic pathways.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diosmetin ameliorates inflammation and apoptosis in the pathomechanism of PCOS through the NRF2/AKT/PPARγ signalling pathway.Journal of ovarian research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, inflammation, and hepatocyte damage. A Western-style diet characterized by excessive n-6 polyunsaturated fatty acid (n-6 PUFA) intake, which is metabolized to pro-inflammatory arachidonic acids (AAs), might contribute to the exacerbation of NASH. Investigating the interactive effects of choline deficiency and n-6 PUFA supplementation on NASH progression, we aimed to elucidate how AA metabolites, such as leukotrienes, prostaglandins, and the CYP2J3/epoxyeicosatrienoic acids (EET) pathway influence disease pathogenesis. Rats were fed one of four diets: choline-sufficient with low n-6 PUFA and high saturated fatty acid (SFA) (C1), choline-sufficient with high n-6 PUFA (C2), choline-deficient with high n-6 PUFA (D1), or choline-deficient with low n-6 PUFA and high SFA (D2). Liver damage, inflammation, and oxidative stress in D1 were more than compared to C2 and D2 groups. Aggravation of NASH in D1 was accompanied by reduced levels of 15-deoxy-Δ12,14-prostaglandin J2 and PPAR-γ, weakening anti-inflammatory effects and lipid metabolism. Decreased CYP2J3 expression along with reduced PPAR-α levels, likely contributed to reduced anti-inflammatory EET levels, while elevated soluble epoxide hydrolase increased pro-inflammatory dihydroxyeicosatrienoic acids. Additionally, higher leukotriene C4 and 15-hydroxyeicosatetraenoic acid levels via the lipoxygenase pathway exacerbated inflammation. The combined pathway alterations in the D1 group increased inflammation, leading to elevated NF-κB expression, Kupffer cell polarization to M1, and lipid peroxidation, with n-6 PUFA interacting with choline deficiency to exacerbate these effects. Correlational analysis revealed significant associations between these pathways and inflammatory/oxidative markers. Our findings suggest that high intake of n-6 PUFA could aggravate NASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.